scholarly journals Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer

2014 ◽  
Vol 5 (3) ◽  
pp. 242-247 ◽  
Author(s):  
Keiko Nunomiya ◽  
Yoko Shibata ◽  
Shuichi Abe ◽  
Sumito Inoue ◽  
Akira Igarashi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Lymphatic Vessel ◽  
Hyaluronan Receptor

scholarly journals Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1

2018 ◽  
Vol 109 (10) ◽  
pp. 3171-3182 ◽  
Author(s):  
Yuta Hara ◽  
Ryota Torii ◽  
Shiho Ueda ◽  
Erina Kurimoto ◽  
Eri Ueda ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Lymphatic Vessel ◽  
Tumor Formation ◽  
Hyaluronan Receptor

scholarly journals Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e41746 ◽  
Author(s):  
Till Plönes ◽  
Alexander Krohn ◽  
Meike Burger ◽  
Hendrik Veelken ◽  
Bernward Passlick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cc Chemokine ◽  
Chemokine Ligand

scholarly journals Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1

2008 ◽  
Vol 158 (2) ◽  
pp. 265-271 ◽  
Author(s):  
Fadil M Hannan ◽  
Nicholas A Athanasou ◽  
James Teh ◽  
Christopher L M H Gibbons ◽  
Brian Shine ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Lymphatic Vessel ◽  
Serum Alkaline Phosphatase ◽  
Fibroblast Growth Factor 23 ◽  
Elevated Serum ◽  
Fibroblast Growth ◽  
Serum Alkaline Phosphatase Activity ◽  
Biochemical Abnormalities ◽  
Hyaluronan Receptor

Oncogenic osteomalacia (OOM) is characterised by tumour production of fibroblast growth factor 23 (FGF23) that results in hypophosphataemia and renal phosphate wasting, reduced 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) synthesis and osteomalacia. Here, we demonstrate the roles of serum FGF23 and 1,25(OH)2D3, together with the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), as biomarkers for OOM. A previously well 52-year-old man presented with a 2-year history of generalised musculoskeletal pain and proximal myopathy. He had hypophosphataemia, elevated serum alkaline phosphatase activity, low serum 1,25(OH)2D3 and a reduced tubular maximum of phosphate/glomerular filtration rate. These findings indicated a diagnosis of OOM, but magnetic resonance imaging (MRI) and octreotide scintigraphy did not identify any tumours. Treatment with oral phosphate and calcitriol resolved the symptoms and biochemical abnormalities within 6 months. Four years later, he relapsed whilst on treatment with oral phosphate and calcitriol. Serum FGF23 concentration was elevated and MRI identified a 2 cm tumour within Hoffa's fat pad of the left knee. Removal of the tumour resulted in a complete resolution of symptoms and normalisation of the serum biochemical abnormalities including serum FGF23. Histology demonstrated a phosphaturic mesenchymal tumour, mixed connective tissue variant (PMTMCT), which revealed immunostaining with anti-LYVE-1 antibody and hence the presence of lymphatic vessels. Serum FGF23 and 1,25(OH)2D3 were found to be reliable biomarkers for OOM. In addition, the demonstration of lymphatics in the PMTMCT helps to distinguish this tumour from most typical benign haemangiomas.

Sign in / Sign up

Export Citation Format

Share Document